A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC).

Trial Profile

A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC).

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2013

At a glance

  • Drugs AT 101 (Primary)
  • Indications Adrenal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2013 New source identified and integrated (Mayo Clinic; 08-001344).
    • 06 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top